February 23rd 2023
A qualitative, interview-based analysis identified 7 distinct roles played by hematologists relating to shared decision making for patients with advanced lymphoma or leukemia.
January 19th 2023
Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid LeukemiaFebruary 24th 2021
A study published in The Lancet Hematology found an increased risk of developing myelodysplastic syndrome and acute myeloid leukemia when patients with cancer were treated with PARP inhibitors compared with placebo.
Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 PandemicMay 28th 2020
Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.
Stephen Schuster, MD, on Prioritizing Patients with Aggressive Lymphomas During COVID-19 PandemicMay 25th 2020
Stephen Schuster, MD, discussed how they are prioritizing patients with more aggressive lymphomas, with emphasis on tumor volume and serum LDH levels during the COVID-19 pandemic.
Expert Discusses Home Treatment for Aggressive Lymphomas Amidst COVID-19 PandemicMay 20th 2020
Stephen Schuster, MD, explained how Penn Medicine is utilizing at-home treatments, which will continue after the pandemic, to maximize safety and reduce hospital traffic during the COVID-19 pandemic.
Stephen Schuster, MD, Talks Adjustments for Treating Patients with Aggressive Lymphomas During COVID-19 PandemicMay 14th 2020
Stephen Schuster, MD, of Penn Medicine discussed testing for COVID-19, telemedicine and how they are adjusting their treatment of patients with aggressive lymphomas during the pandemic.
Strategies Combining Nivolumab Show Promise for Classic Hodgkin LymphomaMay 11th 2020
Researchers found that 2 studied strategies, which combined nivolumab and doxorubicin, vinblastine, and dacarbazine, are feasible, highly effective, and result in excellent 12-month progression-free survival.
Continued Treatment with SGX301 in Patients with CTCL Increases Response RatesMay 10th 2020
SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.
DETECT-A Blood Test Combined with PET-CT May Lead to Surgery with Intent to CureMay 8th 2020
In this study, the feasibility and safety of DETECT-A coupled with PET-CT imaging to detect cancer was evaluated using a prospective, interventional study of 10,006 women not previously known to have cancer.
Early Results from the Phase Ia/b Dose Escalation Trial of CG-806 in CLL/SLL and NHLApril 28th 2020
The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available.
FDA Grants RMAT Designation to Tisagenlecleucel for Relapsed/Refractory Follicular LymphomaApril 22nd 2020
The FDA granted regenerative medicine advanced therapy designation to tisagenlecleucel for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma.
ILROG Recommends Alternative Radiation Treatment Schemes in Blood Cancer During COVID-19 PandemicApril 21st 2020
The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.
Economic Evaluation of CAR T-Cell Therapies by Site Care for Large B-Cell LymphomasApril 16th 2020
Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.
AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19April 15th 2020
AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.
Moving toward Nonchemotherapy-Based Approaches in Follicular LymphomaApril 9th 2020
Michael L. Grossbard, MD, suggested that chemo-free regimens, including PI3K inhibitors and a more widespread use of allogeneic stem cell transplant, are being explored as treatment options in this space.
Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLLApril 6th 2020
Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival.
New Genetic Structural Variants Identified in Childhood LeukemiasMarch 13th 2020
Previously unrecognized genetic structural variants in childhood leukemias could be used to evaluate the presence of minimal residual disease during chemotherapy and help to determine response to various therapies.
Use of Post-HSCT Cyclophosphamide Improves Transplantation Outcomes for AML/MDSMarch 12th 2020
Hematopoietic stem cell transplantation (HSCT) with prior use of checkpoint inhibitors was found to be feasible in patients with acute myeloid leukemia and/or myelodysplastic syndromes and the use of post-HSCT cyclophosphamide as graft-versus host disease prophylaxis improves outcomes.
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality RatesMarch 11th 2020
A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.
FDA Grants Orphan Drug Designation to Umbralisib for Patients with Follicular LymphomaMarch 10th 2020
The FDA granted orphan drug designation to umbralisib based on results from the phase IIb UNITY-NHL trial cohort of patients with follicular lymphoma who have received at least 2 prior lines of therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.